In reply to the letter to the editor regarding “Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study”

2020 ◽  
Vol 408 ◽  
pp. 116511
Author(s):  
Corrado Zenesini ◽  
Elisa Baldin ◽  
Luca Vignatelli ◽  
Roberto D'Alessandro
2019 ◽  
Vol 405 ◽  
pp. 116421 ◽  
Author(s):  
Corrado Zenesini ◽  
Elisa Baldin ◽  
Luca Vignatelli ◽  
Elisabetta Poluzzi ◽  
Ippazio Antonazzo ◽  
...  

2005 ◽  
Vol 20 (6) ◽  
pp. 719-725 ◽  
Author(s):  
Alexis Elbaz ◽  
Brett J. Peterson ◽  
James H. Bower ◽  
Ping Yang ◽  
Demetrius M. Maraganore ◽  
...  

1998 ◽  
Vol 73 (8) ◽  
pp. 724-727 ◽  
Author(s):  
David R. Chabolla ◽  
Demetrius M. Maraganore ◽  
J. Eric Ahlskog ◽  
Peter C. O'Brien ◽  
Walter A. Rocca

2019 ◽  
Vol 31 (3) ◽  
pp. 196-200 ◽  
Author(s):  
Allison L. Hansen ◽  
Janina Krell-Roesch ◽  
Kristin A. Kirlin ◽  
Martin M. Limback-Stokin ◽  
Kimberly Roesler ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Álvaro Réa-Neto ◽  
Bruna C. Dal Vesco ◽  
Rafaella S. Bernardelli ◽  
Aline M. Kametani ◽  
Mirella C. Oliveira ◽  
...  

Background. Parkinson’s disease affects approximately 1% of the worldwide population older than 60 years. This number is estimated to double by 2030, increasing the global burden of the disease. Patients with Parkinson’s disease are hospitalized 1.5 times more frequently and for longer periods than those without the disease, increasing health-related costs. Objective. To compare the characteristics and outcome of patients with and without Parkinson’s disease admitted to intensive care units (ICUs). Methods. Historical cohort study of ICU admissions in a Brazilian city over 18 years. All patients with Parkinson’s disease identified were matched for age, sex, year, and place of hospitalization with patients without the disease randomly selected from the same database. Results. The study included 231 patients with Parkinson’s disease (PD group) and 462 controls without the disease (NPD group). Compared with patients in the NPD group, those in the PD group were more frequently admitted with lower level of consciousness and increased APACHE II severity score but required less frequently vasoactive drugs. In total, 42.4% of the patients in the PD group were admitted to the ICUs due to sepsis or trauma. Although these patients had longer hospital stay, the mortality rates were comparable between groups. Parkinson’s disease was not associated with mortality, even when controlled for associated factors of disease severity. Conclusion. Although patients with Parkinson’s disease were admitted with higher severity scores and remained in the ICU for a longer time, their mortality rate was not higher than that in patients without the disease.


BMJ Open ◽  
2018 ◽  
Vol 8 (8) ◽  
pp. e023302 ◽  
Author(s):  
Hsiu-Feng Wu ◽  
Li-Ting Kao ◽  
Jui-Hu Shih ◽  
Hui-Han Kao ◽  
Yu-Ching Chou ◽  
...  

ObjectivesMany researchers have expected pioglitazone to serve as an effective neuroprotective agent against Parkinson’s disease (PD). Therefore, we conducted this cohort study to investigate the association between pioglitazone use and PD by using a large Asian population-based dataset in Taiwan.DesignRetrospective cohort study.SettingTaiwan.Participants7906 patients with diabetes who had received pioglitazone were defined as the study cohort, and 7906 matched patients with diabetes who had not received pioglitazone were defined as the comparison cohort.Primary and secondary outcome measuresWe tracked each patient individually over a 5-year follow-up period to identify those diagnosed as having PD during this period. We performed Cox proportional hazard regression analyses to evaluate the HRs for PD between the study and comparison cohorts.ResultsThe findings indicated that among the sampled patients, PD occurred in 257 (1.63%): 119 (1.51%) pioglitazone users and 138 (1.75%) non-users. The adjusted HR for PD within the follow-up period was 0.90 (95% CI: 0.68 to 1.18) in the patients who had received pioglitazone compared with the matched patients who had not received pioglitazone. Moreover, this study revealed that pioglitazone use was not associated with PD incidence in men (HR: 1.06, 95% CI: 0.71 to 1.59) or women (HR: 0.84, 95% CI: 0.61 to 1.15).ConclusionsThis study did not find the relationship between pioglitazone use and PD incidence, regardless of sex, among an Asian population of patients with diabetes.


Sign in / Sign up

Export Citation Format

Share Document